Alcobra Enrolls First Patient in MG01CI Study for Patients With PI-ADHD

Alcobra Ltd.

, an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug, MG01CI, to treat Attention Deficit/Hyperactivity Disorder (ADHD), announced today that it has enrolled its first patient in a placebo-controlled clinical study designed to compare the efficacy of varied dosage levels of MG01CI to treat and improve executive dysfunctions in adult patients with Predominantly Inattentive Attention Deficit/Hyperactivity Disorder (PI-ADHD). The clinical study will enroll up to 36 adult PI-ADHD patients and is expected to be completed in the fourth quarter of 2013. "This study adds a new dimension to our clinical development of MG01CI for the treatment of ADHD and potentially other cognitive disorders as well. While this study will not impact the launch of our Phase III trial scheduled for later this year, we believe it will strengthen and broaden our understanding of the clinical benefits of MG01CI compared to existing non-stimulant medications," commented Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra Ltd. "We have expanded the cognitive tests being administered in this comparative study, which will offer us a greater understanding of the impact MG01CI is having on patients beyond